PEDIATRICS Vol. 75 No. 3 March 1985, pp. 547-552
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dolgin, M. J.
Right arrow Articles by Siegel, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dolgin, M. J.
Right arrow Articles by Siegel, S. E.

Anticipatory Nausea and Vomiting in Pediatric Cancer Patients

Michael J. Dolgin PhD1, Ernest R. Katz PhD1, Kathy McGinty RN1, and Stuart E. Siegel MD1

1 From the Division of Hematology-Oncology, Childrens Hospital of Los Angeles, and Department of Pediatrics, University of Southern California, School of Medicine, Los Angeles

The purpose of this study was to determine the prevalence and correlates of anticipatory nausea and vomiting in a sample of pediatric patients with cancer who were receiving outpatient chemotherapy. Forty male and female patients representing a broad range of diagnoses were interviewed with their parents concerning nausea and vomiting before and after chemotherapy. Anticipatory nausea was reported by 28.8% of the sample; anticipatory vomiting was present in 20% of the sample. An additional 9% had experienced anticipatory nausea and vomiting in the past but not currently. Anticipatory nausea and vomiting was positively correlated with the emetic potential of chemotherapeutic regimens and the severity of nausea and vomiting after chemotherapy; anticipatory nausea and vomiting most often developed within the first 4 months of treatment. Onset of anticipatory nausea and vomiting usually occurred two to four hours before treatment and was most severe at the actual time of drug administration. Considerable interpatient variability was observed, with treatment-related factors accounting for only 22% of the variance in the occurrence of anticipatory nausea and vomiting. These findings are considered within a behavioral framework for understanding conditioned aversions in pediatric patients with cancer. Implications for patient education, future research on the prediction of children at risk, and intervention are discussed.

Key Words: anticipatory nausea and vomiting • conditioning • cancer therapy • chemotherapy

Submitted on December 5, 1983
Accepted on April 24, 1984




This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
E S Antonarakis and R D W Hain
Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice
Arch. Dis. Child., September 1, 2004; 89(9): 877 - 880.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al.
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971.
[Full Text] [PDF]